Paloma Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-92
| Closed | -$82.7K | – | 1450 |
|
|
2024
Q2 | $83.3K | Buy |
+92
| New | +$73.6K | ﹤0.01% | 1093 |
|
|
2023
Q3 | – | Sell |
-4
| Closed | -$1.88K | – | 840 |
|
|
2023
Q2 | $1.88K | Sell |
4
-4,624
| -100% | -$1.94M | ﹤0.01% | 701 |
|
|
2023
Q1 | $1.59M | Buy |
4,628
+4,171
| +913% | +$1.41M | 0.06% | 282 |
|
|
2022
Q4 | $167K | Buy |
457
+431
| +1,658% | +$153K | 0.01% | 736 |
|
|
2022
Q3 | $8K | Buy |
+26
| New | +$8.24K | ﹤0.01% | 955 |
|
|
2022
Q2 | – | Sell |
-9,636
| Closed | -$2.89M | – | 1450 |
|
|
2022
Q1 | $2.76M | Sell |
9,636
-3,764
| -28% | -$969K | 0.08% | 166 |
|
|
2021
Q4 | $3.7M | Buy |
+13,400
| New | +$3.4M | 0.06% | 283 |
|
|
2021
Q3 | – | Sell |
-19,438
| Closed | -$4.46M | – | 1543 |
|
|
2021
Q2 | $4.46M | Sell |
19,438
-41,733
| -68% | -$8.38M | 0.08% | 218 |
|
|
2021
Q1 | $11.4M | Buy |
+61,171
| New | +$12M | 0.24% | 68 |
|
|
2020
Q4 | – | Sell |
-176,854
| Closed | -$26.2M | – | 1974 |
|
|
2020
Q3 | $26.2M | Buy |
176,854
+174,943
| +9,155% | +$27.1M | 0.66% | 13 |
|
|
2020
Q2 | $313K | Sell |
1,911
-1,289
| -40% | -$198K | 0.01% | 1455 |
|
|
2020
Q1 | $444K | Sell |
3,200
-18,568
| -85% | -$2.55M | 0.02% | 545 |
|
|
2019
Q4 | $2.86M | Sell |
21,768
-62,981
| -74% | -$7.3M | 0.04% | 446 |
|
|
2019
Q3 | $9.48M | Buy |
84,749
+49,208
| +138% | +$5.48M | 0.2% | 76 |
|
|
2019
Q2 | $3.94M | Buy |
35,541
+31,226
| +724% | +$3.68M | 0.07% | 234 |
|
|
2019
Q1 | $560K | Sell |
4,315
-72,537
| -94% | -$8.82M | 0.01% | 1002 |
|
|
2018
Q4 | $8.89M | Buy |
76,852
+43,251
| +129% | +$4.83M | 0.27% | 55 |
|
|
2018
Q3 | $3.6M | Buy |
+33,601
| New | +$3.36M | 0.07% | 256 |
|
|
2018
Q2 | – | Sell |
-14,109
| Closed | -$1.09M | – | 1958 |
|
|
2018
Q1 | $1.09M | Sell |
14,109
-10,518
| -43% | -$847K | 0.02% | 947 |
|
|
2017
Q4 | $2.08M | Buy |
+24,627
| New | +$2.1M | 0.03% | 650 |
|
|
2017
Q3 | – | Sell |
-22,133
| Closed | -$1.82M | – | 2287 |
|
|
2017
Q2 | $1.82M | Buy |
22,133
+4,023
| +22% | +$328K | 0.02% | 820 |
|
|
2017
Q1 | $1.52M | Buy |
18,110
+9,591
| +113% | +$768K | 0.02% | 969 |
|
|
2016
Q4 | $627K | Buy |
8,519
+992
| +13% | +$73.9K | 0.01% | 1419 |
|
|
2016
Q3 | $604K | Sell |
7,527
-3,365
| -31% | -$269K | 0.01% | 1307 |
|
|
2016
Q2 | $858K | Sell |
10,892
-8,968
| -45% | -$675K | 0.01% | 1255 |
|
|
2016
Q1 | $1.43M | Buy |
19,860
+14,572
| +276% | +$1.1M | 0.02% | 652 |
|
|
2015
Q4 | $446K | Sell |
5,288
-25,139
| -83% | -$2.09M | 0.01% | 1098 |
|
|
2015
Q3 | $2.55M | Buy |
30,427
+10,894
| +56% | +$920K | 0.06% | 264 |
|
|
2015
Q2 | $1.63M | Buy |
19,533
+12,990
| +199% | +$990K | 0.03% | 531 |
|
|
2015
Q1 | $475K | Buy |
+6,543
| New | +$466K | 0.01% | 803 |
|
|
2014
Q4 | – | Sell |
-5,806
| Closed | -$376K | – | 1269 |
|
|
2014
Q3 | $376K | Sell |
5,806
-1,694
| -23% | -$107K | 0.02% | 638 |
|
|
2014
Q2 | $466K | Buy |
+7,500
| New | +$447K | 0.02% | 612 |
|
|
2014
Q1 | – | Sell |
-6,480
| Closed | -$330K | – | 865 |
|
|
2013
Q4 | $330K | Buy |
+6,480
| New | +$324K | 0.02% | 764 |
|
|
2013
Q3 | – | Sell |
-26,113
| Closed | -$1.28M | – | 1074 |
|
|
2013
Q2 | $1.28M | Buy |
+26,113
| New | +$1.42M | 0.07% | 229 |
|
Other funds holding LLY
Paloma Partners's LLY Position: Q3 2024 in Review
Paloma Partners sold out of Eli Lilly (LLY) in Q3 2024, closing a stake of 92 shares — an estimated $82.7K sold.
Paloma Partners first reported a position in LLY in Q2 2013 and held it in 34 quarters. The position peaked at $26.2M in Q3 2020. 3,657 funds tracked by Wall St. Rank hold LLY as of Q3 2024.
- Paloma Partners reported no remaining Eli Lilly position as of Q3 2024 after selling out during the quarter.
- Paloma Partners sold 92 Eli Lilly shares in Q3 2024, an estimated $82.7K.
- Paloma Partners first reported a position in Eli Lilly in Q2 2013 and held it in 34 quarters.
- Paloma Partners's Eli Lilly position peaked at $26.2M in Q3 2020.
- 3,657 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2024.
Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.